In the United States, the brand name Lucemyra<unk>  HCl) is approved for the "mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults," for a treatment duration of 14 days. In the United Kingdom,<unk>  is commonly used in conjunction with the opioid receptor antagonist naltrexone in rapid detoxification cases. When these two drugs are paired, naltrexone is administered to induce an opioid-receptor blockade sending the subject into immediate withdrawal and accelerating the detoxification process, while<unk>  is given to relieve the symptoms associated with the withdrawal including chills, sweating, stomach cramps, muscle pain, and runny nose. Opioid withdrawal The United Kingdom's National Institute for Health and Care Excellence (NICE) guidelines recommend the use of methadone or buprenorphine as first-line agents in the management of opioid use disorder. However,<unk>  is considered an acceptable alternative for people with mild or uncertain opioid dependence in need of short-term detoxification.<unk>  is not an opioid. It does not eliminate the symptoms of opioid withdrawal but reduces them. Indeed, one suggested use for<unk>  is to ease withdrawal symptoms of methadone dependence. Its use is approved in the United States for up to 14 days. Other clinical uses The possibility of using<unk>  to treat alcohol withdrawal symptoms has been investigated, and has not yet been shown to be an effective treatment. It is also used in treatment of cases suffering from postmenopausal hot flashes. Special populations<unk> 's safety in pregnancy or in the setting of breastfeeding are unknown. Caution is warranted if chronic kidney impairment is present.
Lofexidine
Setiptiline
Pramocaine
Veratridine
Tocainide
Ivabradine
Nefopam
Procainamide